The PD-1/PD-L1 inhibitor group showed a PFS benefit in patients with NSCLC, SCLC, ESCC and NPC (Figure 3; Supplementary Figure S13). This evidence concerns the gene PDCD1 and nasopharyngeal carcinoma.